Zenas BioPharma Announces Successful Phase 3 INDIGO Study of Obexelimab in IgG4-RD
Zenas BioPharma has announced positive top-line results from its pivotal Phase 3 INDIGO clinical trial evaluating obexelimab for the treatment of IgG4-Related Disease (IgG4-RD). IgG4-RD is a rare, systemic, chronic fibroinflammatory condition that can affect multiple organs, including the pancreas, salivary glands, and kidneys, often leading to organ dysfunction or failure if untreated. Obexelimab is a first-in-class, high-affinity, bifunctional monoclonal antibody that mimics the action of antigen-antibody complexes by co-engaging CD19 and FcγRIIb to inhibit B-cell lineage activity....
